Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2015

View Archived Issues

Genentech's LGR5-targeting ADC inhibits growth of colon cancer

SMRX-11: A clot-specific streptokinase

Novel CSF-1R inhibitor shows promising results for bone tumors

Italian and U.S. academic team patents ASAH1 inhibitors

AbbVie patents V1bR ligands

Chengdu Bestchiralbio announces DPP IV inhibitors

Roche reports anti-HBV agents

Eisai presents splicing factor 3B modulators

Calitor Sciences and Sunshine Lake Pharma present PI3K inhibitors

European Comission approves Horizon's Ravicti

Managed access program for ixazomib begins for patients with multiple myeloma

Heptares enters strategic drug discovery collaboration with Pfizer

Vericiguat holds promise for heart failure

Applications seeking approval of Stelara for Crohn's disease submitted by Janssen

Dose expansion implemented in study of immunomodulator EF-022 in patients with solid tumors

Phase I study of Intercept's INT-767 begins

FDA approves Empliciti for previously treated multiple myeloma

Novel kinase inhibitor shows promise for the treatment of HCC

Valneva releases data from phase II study of prophylactic C. difficile vaccine candidate

Phase III results for MD-1003 in MS patients with chronic visual loss following optic neuritis

Almirall to acquire dermatology specialist Poli Group

Puma Biotechnology reports plans for neratinib MAA filing

Roche licenses Proximagen VAP-1 inhibitor for inflammatory disease

Baxalta's Adynovate launched for the treatment of hemophilia in adult patients

Mallinckrodt closes sale of CMDS business to Guerbet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...